ROCHESTER, N.Y., May 28, 2026— CooperVision is accelerating product availability for U.S. eye care professionals by adding more than 1,500 new parameters of Biofinity® XR toric contact lenses to its domestic inventory. With over 2,300 parameters now available for next‑day shipping—spanning both trial lenses and six‑packs—practices can access a wider range of prescriptions with greater speed. The following parameters are now fulfilled directly from West Henrietta, NY:
Cylinder | Sphere | Axis |
-2.75 | +8.00 to -10.00 (0.50 steps above +/- 6.00)
Plano to -6.00 (0.50 steps only) | 10° to 180° (10° steps)
5° and 175° |
-3.25 | Plano to -10.00 (0.50 steps above -6.00)
Plano to -6.00 (0.50 steps only) | 10° to 180° (10° steps)
5° and 175° |
-3.75 | Plano to -10.00 (0.50 steps above -6.00) | 10° to 180° (10° steps)
|
With next-day delivery from U.S. inventory, practices can schedule follow‑up appointments sooner, reduce delays when prescription adjustments are needed, and streamline the overall fitting process. Throughout 2026, CooperVision will also continue transitioning additional Biofinity® XR toric powers from its U.K. manufacturing facility to its Scottsville, N.Y. site, resulting in shortened shipping times for even more customers.
“CooperVision is a world leader in toric lens innovation,*1 and we’re committed to giving patients faster access to the most prescribed toric lens on the market,2 including many who require extended range prescriptions,”3 said Doug Brayer, Director of Marketing, Frequent Replacement Brands, CooperVision. “By adding some of the highest demand Biofinity® XR toric parameters to our domestic inventory and continuing to expand U.S. manufacturing, we are dramatically improving the fulfillment time for these made-to-order lenses.”
Biofinity® toric and Biofinity® XR toric are available in more than 37,000 prescription options,4 providing correction for 99.9% of patients with astigmatism.3
# # #
About CooperVision
CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.
Media Contact
Heather Kowalczyk, APR
McDougall Communications for CooperVision
heather@mcdougallpr.com or +1.585.434.2148
*Combination of 2024 market research based on global volume data, internal estimates, and competitive data.
References:
1. CVI data on file, 2025.
2. CVI data on file, 2023. US industry reports and internal estimates.
3. CooperVision data on file 2021. Rx coverage database; 14 to 70 years.
4. CVI data on file, 2023. Based on total number of prescription option combinations (for sphere, cylinder, and axis) manufactured.
19163 01/26